Background: The contribution of monocyte activation in the development of HIV-associated neurocognitive disorders is not completely understood. This study aimed to explore the predictive value of peripheral monocyte/macrophage (M/M) phenotypes on the evolution of cognitive performance in a population of virologically suppressed HIV-infected patients. Setting: Prospective, observational, longitudinal study. Methods: HIV-1-infected patients with HIV-RNA <50copies/mL for >12 months underwent neuropsychological examination at baseline and after 1 year. Cognitive performance was evaluated using Z-transformed scores, and neurocognitive impairment (NCI) was defined according to Frascati criteria. Peripheral M/M phenotypes (classic CD14 ++ CD16 -, intermediate CD14 ++ CD16 +, and nonclassic CD14 + CD16 ++) and specific surface activation markers (eg, CD163, CD11b, and CD38) were evaluated using flow cytometry at baseline. Predictive value of peripheral M/M phenotypes on the evolution of cognitive performance over 1-year follow-up was also evaluated. Results: Overall, 54 patients [85.2% men, median age 50 years (range 27-60 years), 27.8% hepatitis C virus coinfected, 48.1% with past AIDS-defining events, median nadir CD4 83 cells/L (range 1-334), median baseline CD4 547 cells/L (range 136-1652)] were enrolled. Proportion of patients with NCI was low, accounting for 13% at baseline and 16.5% after 1 year (P = 0.687). Memory was the only single domain in which decreased performance after 1 year was observed (-0.25 Z-score, P = 0.025). In patients with significant decrease (≥0.5 SD) in memory performance (n = 20), significantly lower CD14 ++ CD16 + CD163 + (% CD14 ++ CD16 +) (P = 0.038) and higher CD14 + CD38 + (% CD14 +) (P = 0.030) levels were observed. Conclusions: In virologically suppressed HIV-infected patients, the evolution of memory performance could be linked to the expression of certain peripheral activated M/M phenotypes. Such associations should be verified in larger populations over the long term.

Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients / M. Fabbiani, A. Muscatello, P. Perseghin, M. Bani, A. Incontri, N. Squillace, G. Lapadula, A. Gori, A. Bandera. - In: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. - ISSN 1525-4135. - 76:2(2017), pp. 219-224. [10.1097/QAI.0000000000001480]

Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients

A. Gori;A. Bandera
2017

Abstract

Background: The contribution of monocyte activation in the development of HIV-associated neurocognitive disorders is not completely understood. This study aimed to explore the predictive value of peripheral monocyte/macrophage (M/M) phenotypes on the evolution of cognitive performance in a population of virologically suppressed HIV-infected patients. Setting: Prospective, observational, longitudinal study. Methods: HIV-1-infected patients with HIV-RNA <50copies/mL for >12 months underwent neuropsychological examination at baseline and after 1 year. Cognitive performance was evaluated using Z-transformed scores, and neurocognitive impairment (NCI) was defined according to Frascati criteria. Peripheral M/M phenotypes (classic CD14 ++ CD16 -, intermediate CD14 ++ CD16 +, and nonclassic CD14 + CD16 ++) and specific surface activation markers (eg, CD163, CD11b, and CD38) were evaluated using flow cytometry at baseline. Predictive value of peripheral M/M phenotypes on the evolution of cognitive performance over 1-year follow-up was also evaluated. Results: Overall, 54 patients [85.2% men, median age 50 years (range 27-60 years), 27.8% hepatitis C virus coinfected, 48.1% with past AIDS-defining events, median nadir CD4 83 cells/L (range 1-334), median baseline CD4 547 cells/L (range 136-1652)] were enrolled. Proportion of patients with NCI was low, accounting for 13% at baseline and 16.5% after 1 year (P = 0.687). Memory was the only single domain in which decreased performance after 1 year was observed (-0.25 Z-score, P = 0.025). In patients with significant decrease (≥0.5 SD) in memory performance (n = 20), significantly lower CD14 ++ CD16 + CD163 + (% CD14 ++ CD16 +) (P = 0.038) and higher CD14 + CD38 + (% CD14 +) (P = 0.030) levels were observed. Conclusions: In virologically suppressed HIV-infected patients, the evolution of memory performance could be linked to the expression of certain peripheral activated M/M phenotypes. Such associations should be verified in larger populations over the long term.
HAND; HIV; immune system; inflammation; monocyte/macrophage activation; neurocognitive disorders; Adolescent; Adult; Biomarkers; Cognition Disorders; Cross-Sectional Studies; Endpoint Determination; Evolution; Molecular; Female; HIV Infections; Humans; Longitudinal Studies; Macrophages; Male; Middle Aged; Monocytes; Phenotype; Prospective Studies; Young Adult; Cognition; Infectious Diseases; Pharmacology (medical)
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
File Dimensione Formato  
Brief_Report___Peripheral_Monocyte_Macrophage.17.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 206.62 kB
Formato Adobe PDF
206.62 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/629062
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact